Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2009-10-02
2010-12-14
Belyavskyi, Michail A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100, C530S387100, C530S388100
Reexamination Certificate
active
07850968
ABSTRACT:
The invention provides methods for modulating cytokine levels, GM-CSF levels and the immune system using CD83 nucleic acids, CD83 polypeptides, anti-CD83 antibodies and factors that influence CD83 activity or expression. The invention also provides mice having a mutant CD83 gene and mice having a transgenic CD83 gene, which are useful for defining the role of CD83 in the immune system and for identifying compounds that can modulate CD83 and the immune system.
REFERENCES:
patent: 5316920 (1994-05-01), Tedder
patent: 5766570 (1998-06-01), Tedder
patent: 6068984 (2000-05-01), Tedder
patent: 6900016 (2005-05-01), Venter
patent: 95/29236 (1995-11-01), None
patent: 97/29781 (1997-08-01), None
patent: 02/074921 (2002-09-01), None
patent: 03/038072 (2003-05-01), None
patent: 03/040170 (2003-05-01), None
Cramer, et al., “Activation-Induced Expression of Murine CD83 on T Cells and Identification of a Specific CD83 Ligand on Murine B Cells,”International Immunol. 12(9):1347-1351, 2000.
Dreher, et al., “cDNA Clone Encoding a Complete Rabbit Immunoglobulin K Light Chain of b4 Allotype,”Proc. Natl. Acad. Sci. USA80:4489-4493, 1983.
Fujimoto, et al., “Dendritic Cell CD83 Provides a Progression Signal Required for CD4+ T Cells Positive Selection in the Thymus,”FASEB Journal15(4):A672, 2001.
Fujimoto, et al., “CD83 Expression Influences CD4+ T Cell Development in the Thymus,”Cell108:755-767, 2002.
Jaton, “Completion of the Analysis of the Primary Structure of the Variable Domain of a Homogeneous Rabbit Antibody to Type III Pneumococcal Polysaccharide,”Biochem. J. 143:723-732, 1973.
Munster, et al., “CD83 Antigen: A Potential New Target for Immunosuppression,”Blood100(11), 2002.
Scholler, et al., “CD83 Is a Sialic Acid-Binding IG-Like Lectin (Siglec) Adhesion Receptor That Binds Monocytes and a Subset of Activated CD8+ T Cells.”Immunol. 166:3865-3872, 2001.
Armitage, et al., “Evidence for a Functional Role of CD83 in T- and B-Cell Responses,”Tissue Antigens4(11):453, Abstract, 1996.
Dallman, “Cytokines and Transplantation: Th1/Th2 Regulation of the Immune Response to Solid Organ Transplants in the Adult,”Curr. Opin. Immunol. 7:632-638, 1995.
Gorczynski, et al., “Interleukin 12 in Combination With Anti-Interleukin 10 Reverses Graft Prolongation After Portal Venous Immunization,”Transplantation60:1337-1341, 1995.
Leonard, et al., “Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against Interleukin 12,”J. Exp. Med. 181:381-386, 1995.
Levy, et al., “Administration of Intragraft Interleukin-4 Prolongs Cardiac Allograft Survival in Rats Treated With Donor-Specific Transfusion/Cyclosporine,”Transplantation60(5):405-406, 1995.
Thai, et al., “Cytokine mRNA Profiles in Mouse Orthotopic Liver Transplantation,”Transplantation59(2):274-281, 1995.
Zhou, et al., “Human Blood Dendritic Cells Selectively Express CD83, A Member of the Immunoglobulin Superfamily,”J. of Immunol. 154(8):3821-3835, 1995.
Chen, et al., “In Vitro Induction of T Cell Anergy by Blocking B7 and Early T Cell Costimulatory Molecule ETC-1/B7-2”Immunity1:147-154, 1994.
Else, et al., “Cytokine-Mediated Regulation of Chronic Intestinal Helminth Infection,”J. Exp. Med. 179:347-351, 1994.
Fowler, et al., “Donor CD4-Enriched Cells of Th2 Cytokine Phenotype Regulate Graft-Versus-Host Disease Without Impairing Allogeneic Engraftment in Sublethally Irradiated Mice,”Blood84:3540-3549, 1994.
Fowler, et al., “Donor Lymphoid Cells of Th2 Cytokine Phenotype Reduce Lethal Graft Versus Host Disease and Facilitate Fully Allogeneic Cell Transfers in Sublethally Irradiated Mice,”Advances in Bone Marrow Purging and Processing: Fourth International Symposium. Prog. Clin. Biol. Res. 389:533-540, 1994.
Maeda et al., “Adoptive Transfer of a Th2-Like Cell Line Prolongs MHC Class II Antigen Disparate Skin Allograft Survival in the Mouse,”International Immunol. 6(6):855-862, 1994.
Paul, et al., “Lymphocyte Responses and Cytokines,”Cell76:241-251, 1994.
Racke, et al., “Cytokine-Induced Immune Deviation As a Therapy for Inflammatory Autoimmune Disease,”J. Exp Med. 180: 1961-1966, 1994.
Simon, et al., “Divergent T-Cell Cytokine Patterns in Inflammatory Arthritis,”Proc. Natl. Acad. Sci. USA91(18):8562-8566, 1994.
Tkakis, et al., “Early Tolerance in Pediatric Liver Allograft Recipients,”J. Pediatr. Surg. 29(6):754-756, 1994.
Seder, et al., “Acquisition of Lymphokine-Producing Phenotype by CD4+ T Cells,”Annu. Rev. Immunol. 12:635-673, 1994.
Bancroft, et al., “Cytokine Production in BALB/C Mice Immunized With Radiation Attenuated Third Stage Larvae of the Filarial Nematode, Brugia Pahangi,”J. of Immunol. 150(4):1395-1402, 1993.
Clerici, et al., “A TH1→TH2 Switch Is a Critical Step in the Etiology of HIV Infection,”Immunology Today14(3):107-111, 1993.
Kuchroo, et al., “Cytokines and Adhesion Molecules Contribute to the Ability of Myelin Proteolipid Protein-Specific T Cell Clones to Mediate Experimental Allergic Encephalomyelitis,”J. of Immunol. 151(8):4371-4382, 1993.
Pearlman, et al., “Induction of Murine T-Helper-Cell Responses to the Filarial Nematode Brugia Malayi,”Infection and Immunity61(3):1105-1112, 1993.
Rapoport, et al., “Interleukin 4 Reverses T Cell Proliferative Unresponsiveness and Prevents the Onset of Diabetes in Nonobese Diabetic Mice,”J. Exp. Med. 178:87-99, 1993.
Yamamura, et al., “Local Expression of Antiinflammatory Cytokines in Cancer,”J. of Clin. Investigation91:1005-1010, 1993.
Khoury, et al., “Oral Tolerance to Myelin Basic Protein and Natural Recovery From Experimental Autoimmune Encephalomyelitis Are Associated With Downregulation of Inflammatory Cytokines and Differential Upregulation of Transforming Growth Factor .Beta.. Interleukin 4, and Prostaglandin E Expression in the Brain,”J. Exp. Med. 176, 1355-1364, 1992.
Kullberg, et al., “Infection With Schistosoma Mansoni Alters Th1/Th2 Cytokine Responses to a Non-Parasite Antigen,”J. of Immunol. 148(10):3264-3270, 1992.
Pisa, et al., “Selective Expression of Interleukin 10, Interferon ┌, and Granulocyte-Macrophage Colony-Stimulating Factor in Ovarian Cancer Biopsies,”Proc. Natl. Acad. Sci. USA89:7708-7712, 1992.
Shearer, et al., “T Helper Cell Immune Dysfunction in Asymptomatic, HIV-1-Seropositive Individuals: The Role of TH1-TH2 Cross-Regulation,”Chem. Immunol. 54:21-43, 1992.
Takeuchi, et al., “Heart Allografts in Murine Systems. The Differential Activation of Th2-Like Effector Cells in Peripheral Tolerance,”Transplantation53:1281-1294, 1993.
Zhou, et al., “A Novel Cell-Surface Molecule Expressed by Human Interdigitating Reticulum Cells, Langerhans Cells, and Activated Lymphocytes Is a New Member of the Ig Superfamily,”J. of Immunol. 149(2):735-742, 1992.
Grzych, et al., “Egg Deposition Is the Major Stimulus for the Production of Th2 Cytokines in Murine Schistosomiasis Mansoni,”J. of Immunol. 146(4):1322-1327, 1991.
Locksley, et al., “Helper T-Cell Subsets in Mouse Leishmaniasis: Induction, Expansion and Effector Function,”Immunol. Today12(3):A58-A61, 1991.
Pearce, et al., “Downregulation of Th1 Cytokine Production Accompanies Induction of Th2 Responses by a Parasitic Helminth, Schistosoma Mansoni,”J. Exp. Med. 173:159-166, 1991.
Sadick, et al., “Cure of Murine Leishmaniasis With Anti-Interleukin 4 Monoclonal Antibody,”J. Exp. Med. 171, 115-127, 1990.
Heinzel, et al., “Reciprocal Expression of Interferon Gamma or Interleukin 4 During the Resolution or Progression of Murine Leishmaniasis. Evidence for Expansion of Distinct Helper T Cell Subsets,”J. Exp. Med. 169:59-72, 1989.
Fauci, “The Human
Appleby Mark W.
Garcia-Martinez Leon Fernando
Proll Sean C
Ramsdell Fred
Staehling-Hampton Karen
Belyavskyi Michail A
Celltech R&D Limited
K&L Gates LLP
LandOfFree
Manipulation of cytokine levels using CD83 gene products does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Manipulation of cytokine levels using CD83 gene products, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Manipulation of cytokine levels using CD83 gene products will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178972